NCT00320216View on ClinicalTrials.gov

A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

June 30, 2004

Study Completion Date

March 31, 2005

Conditions
Psoriasis
Interventions
DRUG

Ustekinumab

Patients will receive subcutaneous injections of ustekinumab (45 or 90 mg).

DRUG

Placebo

Patients in the placebo group will receive placebo medication.

Sponsors

Lead Sponsor

Centocor, Inc.
All Listed Sponsors
lead

Centocor, Inc.

INDUSTRY